Glutaredoxin-1 and Others Antioxidants Enzymes in Two Subtypes (B-cell and T-cell) of Acute Lymphoblastic Leukemia Patients

The 5-year event-free viability for acute lymphoblastic leukemia (ALL) have enhanced in many study groups due to modern paediatric clinical trials, however T-cell ALL results are still lagging by 5–10% in most studies. The goal of this study was to measure the Glutaredoxin-1(Grx1) as an antioxidant, and also to measure each of the methionine sulfoxide reductaseA(MsrA),myeloperoxidase(MPO), catalase(CAT), xanthine oxidase(XO), glutathione (GSH), albumin (Alb), and complete blood counts (CBC) in two subtypes (B-cell and T-cell) of ALL patients compared with control group between the ages of two and fifteen years. Revealed with the results of this study, Grx1, CAT, MDA levels increased statistically significantly in two subtypes of acute lymphocytic leukemia Patients compared with control group, but MsrA, GSH, Alb, and CBC levels declined considerably in two subtypes for patients compared with control group. Finally MPO have non-significant difference in compared.The study concluded that there was a high increase in the level of Grx1, which participates in rescuing blood components from the process of breakdown in which a decrease was observed n for two subtypes (B-cell and T-cell), in addition to a decrease in MsrA, GSH, which works to repair the damage occurring in the proteins of cell components, including blood components, malignant B cells are particularly sensitive in contrast to the T cell.